Advanced Lung Cancer
Conditions
Interventions
Experimental group:68Ga-NODAGA-SNA006 PET-CT imaging
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: General 1. Age 18 - 70 years (including boundary values); 2. Those who have the capacity to act, and voluntarily participate in this clinical study, and sign the informed consent form (ICF); 3. Those with a physical condition (ECOG) score of 0 - 2; 4. Those with a basal heart rate of 60-100 beats/min (including boundary value); 5. Blood pressure measurement 6 months. Laboratory tests 1. Blood routine: white blood cell >=3.0×10^9/L, neutrophil count>=1.5×10^9/L; Platelet >=75×10^9/L; Hemoglobin >=90g/L; 2. Liver function: total bilirubin (TBIL) <=2.5 times the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) both <=3 times ULN; 3. Renal function: blood creatinine (Scr) and urea (BUN) < = 1.5 times ULN.
Exclusion criteria
Exclusion criteria: General 1. Those who are unable to conduct visits in accordance with the provisions of this clinical trial protocol, or receive relevant examinations or treatments; 2. Those whose nutritional status is extremely poor and cannot tolerate the test; 3. Patients with major diseases or other malignant tumors (except those who have been cured one year ago or do not need additional treatment); 4. Those who are known to be severely allergic to SNA006, similar drugs or excipients; Specialty 1. Patients with brain metastases; Laboratory tests 1. Serum virology examination: those who have positive results of hepatitis B virus surface antigen, hepatitis C virus antibody, syphilis-specific antibody or human immunodeficiency virus antibody cannot be confirmed as negative; 2. Those with total protein < 50g/L or albumin < 30g/L at screening; other 1. Patients who have not recovered from severe infection; 2. Drug/alcohol abuse and severe mental disorders; 3. Those with claustrophobia, emotional instability, acute persistent spasms or inability to keep both arms raised and lie flat for 15-30 minutes; 4. Those who have participated in any other clinical trials within 3 months before screening; 5. Females who are pregnant or breastfeeding; 6. Those who are considered by the investigator to be unsuitable to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Standardized Uptake Value, SUV;Imaging evaluation;Treatment response evaluation;Prognosis evaluation; | — |
Countries
China
Contacts
Public ContactYifan Zhang
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed